XTalks

JANUARY 21, 2025

The Onclarity HPV reagent pack extraction combo. Companion diagnostic for Pfizers hemophilia B gene therapy Beqvez (idanacogene elaparvovec-dzkt). The test is designed for identifying individuals with moderate to severe hemophilia B (congenital factor IX [FIX] deficiency) who may benefit from the gene therapy Beqvez.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

Advarra

NOVEMBER 29, 2022

The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. Recent Problems in Cell and Gene Therapy Development. Current Regulatory Trends in Cell & Gene Therapy. Trend One: Expected Growth in Cell and Gene Therapy IND filings.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Moreover, the manual protocols require extensive manipulation, costly reagents and long duration of skilled genomic library production.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

Roots Analysis

FEBRUARY 23, 2022

Over the past few years, several companies have started offering a diverse range of genome sequencing products and services using various second and third generation sequencing technologies. In addition to industry players, various academic institutes have filed multiple patents in this domain.

Genetics 52

Genetics DNA RNA Reagent 52

The Pharma Data

JANUARY 24, 2021

. “We are excited to welcome Chris, a highly regarded drug developer and team builder who brings to Notch great depth of experience and expertise in development of cell therapies, gene editing, and cell engineering spanning discovery through IND,” said David Main , President and Chief Executive Officer of Notch.

Engineer 52

Engineer Gene Editing Genome Genomics 52

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. Financial details of the agreement were not disclosed.

Drugs 52

Drugs Gene Editing Genomics Genome 52

The Pharma Data

JANUARY 20, 2021

Laboratory Implementation Laboratory reagents for performing the test commercially have been designed and are currently being validated in preparation for regulatory submission to CMS/CLIA with a view to targeting sales in the USA initially. MELBOURNE, Australia, Jan.

Genetics 40

Genetics Reagent Biobanking Production 40

XTalks

JANUARY 6, 2025

Gene Editing CRISPR-Cas9 and related gene-editing technologies continue to advance, and today they are widely used to study and develop therapeutic approaches for a broad range of human diseases. As of March 18, 2024, the FDA has approved 36 gene therapies, with an additional 500 therapies in the pipeline. billion by 2031.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111

Roots Analysis

JANUARY 27, 2025

Gene Identification: The process starts with identifying the gene that codes for the desired protein i.e. gene of interest. This can be done through various techniques such as PCR, DNA sequencing or gene synthesis.

Protein 40

Protein Reagent Marketing Gene 40